All explainers
Every published explainer, newest first. Filter by topic or section.

When Pain Conditions Precede IBD: What a 2026 Systematic Review Reveals
Many people with IBD spent years navigating IBS, chronic pelvic pain, endometriosis, or fibromyalgia before their diagnosis arrived. A 2026 systematic review examined whether these chronic overlapping pain conditions are predisposing or perpetuating factors for IBD, finding a significant bidirectional association with implications for how patients are understood and assessed.

Clostridioides Difficile and IBD: What a 2026 Meta-Analysis Found About Antibiotic Treatment
IBD patients face higher rates of C. difficile infection, and the available antibiotics do not perform equally. A 2026 systematic review and meta-analysis pooling 643 IBD patients found that vancomycin was associated with half the recurrence rate of metronidazole, while calling for stronger prospective evidence.

What the Cochrane Evidence Says About Certolizumab Pegol for Crohn's Disease
A 2022 Cochrane systematic review examined randomised trial data on certolizumab pegol (Cimzia) in Crohn's disease and found it significantly more effective than placebo for maintaining remission in patients who responded to induction therapy. Certolizumab is structurally unique among anti-TNF biologics, with implications for certain groups of patients. Here is what the evidence shows.

Comparing All Biologics for Crohn's Disease: What a 2026 Cochrane Network Meta-Analysis Found
A June 2026 Cochrane network meta-analysis pooled evidence from 94 randomised controlled trials to rank biologic drugs for Crohn's disease side by side. The analysis found high-certainty evidence that ustekinumab is the most effective biologic for inducing remission. Here is what the results mean for patients.

IBD and Ankylosing Spondylitis: New Research Confirms the Causal Link Your Doctor May Not Have Mentioned
Many people with inflammatory bowel disease also live with persistent back pain or stiffness and never connect the two. A 2026 meta-analysis using genetic evidence found that the association between IBD and ankylosing spondylitis is not coincidental: it is causal, and it runs in both directions.

What Two Cochrane Reviews Found About Infliximab for Crohn's Disease
Two Cochrane systematic reviews pull together nineteen randomised trials on infliximab in Crohn's disease. Here is what two decades of trial data show about inducing and maintaining remission, and what the evidence does not yet settle.

What the Cochrane Evidence Says About Vedolizumab for Crohn's Disease
A 2023 Cochrane systematic review and meta-analysis pooled randomised trial data on vedolizumab in Crohn's disease and found it more effective than placebo for both inducing and maintaining remission. Here is what those results mean for patients living with Crohn's.

Fecal Microbiota Transplantation for Ulcerative Colitis: What a 2026 Meta-Analysis of Trials Found
A 2026 meta-analysis pooled six randomised trials in ulcerative colitis and found FMT roughly doubled clinical remission rates compared to controls. A plain-language account of what the numbers actually say, and what they do not yet conclude.

Your Blood Count Already Tracks IBD Activity: What a 2026 Systematic Review Found About RDW
Every routine full blood count includes a value called red cell distribution width. A 2026 systematic review and meta-analysis found this commonly overlooked number rises during IBD flares and falls in remission, and that a simple cutoff can distinguish active from quiescent disease with meaningful accuracy.

Can Psychological Support Help Manage IBD? What the 2025 Cochrane Review Found
A 2025 Cochrane systematic review and meta-analysis examined whether psychological interventions, including cognitive behavioural therapy, mindfulness, and psychotherapy, improve outcomes for people with inflammatory bowel disease. Here is an evidence-honest account of what the data showed.

Can Gut Bacteria Predict Whether Infliximab Works? A 2026 Review of the Evidence in Children With IBD
A 2026 systematic review identified specific gut microbiome patterns that appear linked to infliximab treatment response in children with IBD, raising the possibility that a stool sample taken before the first infusion could help predict which patients are most likely to benefit from the drug.

A Training Belt Helped New Stoma Patients Build Skills and Ease Anxiety: What a 2026 Trial Found
A 2026 randomised controlled study published in Nursing Open found that intestinal stoma patients who practised care using a specially designed training belt showed stronger skills, better adjustment, and lower anxiety than those who received standard instruction alone.